Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 5
1973 1
1974 2
1975 1
1977 1
1979 1
1983 1
1984 1
1985 2
1986 1
1987 1
1988 3
1989 2
1990 1
1992 2
1993 1
1996 2
1997 1
2004 1
2009 1
2013 1
2014 2
2015 3
2016 3
2017 2
2018 2
2019 3
2020 3
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: scalzo m. J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5. J Nucl Med. 2019. PMID: 30291192 Free article. Clinical Trial.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Among authors: scalzo m. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: scalzo m. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.
Dhiantravan N, Violet J, Eapen R, Alghazo O, Scalzo M, Jackson P, Keam SP, Mitchell C, Neeson PJ, Sandhu S, Williams SG, Moon D, Lawrentschuk N, Azad A, Hofman MS, Murphy DG. Dhiantravan N, et al. Among authors: scalzo m. Eur Urol Focus. 2021 Mar;7(2):234-237. doi: 10.1016/j.euf.2020.09.021. Epub 2020 Nov 7. Eur Urol Focus. 2021. PMID: 33172774
Prognostic role of maspin expression in melanoma: probably far from clinical use.
Ribero S, Senetta R, Osella-Abate S, Scalzo MS, Castellano I, Lentini F, Baboi AP, Fierro MT, Sapino A, Cassoni P. Ribero S, et al. Among authors: scalzo ms. Histopathology. 2017 Jul;71(1):158-162. doi: 10.1111/his.13188. Epub 2017 Apr 3. Histopathology. 2017. PMID: 28211082 No abstract available.
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. Martinengo C, et al. Among authors: scalzo ms. Cancer Res. 2014 Nov 1;74(21):6094-106. doi: 10.1158/0008-5472.CAN-14-0268. Epub 2014 Sep 5. Cancer Res. 2014. PMID: 25193384
48 results